Patent 10555953 was granted and assigned to Novaliq on February, 2020 by the United States Patent and Trademark Office.
The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The invention further provides kits comprising such compositions.